CXCR4 and endometrial cancer: Aiming to offer a therapeutic option for the treatment of endometrial cancer (EC) patients currently lacking an effective therapy [9], we demonstrated that 64.4% of EC patients overexpress high membrane CXCR4 expression, therefore making them candidates for CXCR4-targeted therapies.